Companies: 10,795·Total market cap: $144.5T

Akero Therapeutics, Inc.

Akero Therapeutics, Inc.

AKRONASDAQHealthcare

$54.65

+$0.00(+0.00%)

Market Cap$4.5B

P/E Ratio—

52W High$58.4

52W Low$21.34

Avg Volume2.6M

Open$54.52

Beta-0.40

Net Income Financials Revenue

Akero Therapeutics, Inc. (AKRO) Net Income & Profit History

Annual & trailing net income, net margin, YoY change, and peer profitability context.

AKRO · net income · updated Jun 8, 2026

Core profitability metrics

AKRO · net income · margin · TTM · CAGR

Net income was −$252.1M for FY2024 (fiscal year ending 2024-12-31), down 66.1% year-over-year. Net profit margin was —.

FY2024 Net Income−$252.1M▼ -66.1% YoY

Trailing 12M (TTM)−$292.8Mtrailing 4 quarters sum

Net Profit Margin——

YoY Change-66.1%—

5-Year CAGRN/AN/A — contains loss years

FormulaNet Margin = Net Income ÷ Revenue × 100TTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /income-statement · US GAAP · USDUpdated: Jun 8, 2026

Annual net income history

Net Income (bars) · Net Profit Margin % (line)

Net IncomeNet LossNet Margin %

▸ FMP /income-statement · Annual · AKRO net income history · AKRO profit margin

Annual net income data

AKRO · net income history · annual / quarterly

Fiscal YearNet IncomeYoY ChangeNet MarginRevenue

FY2024Loss−$252.1M▼ 66.1%—$0

FY2023Loss−$151.8M▼ 35.5%—$0

FY2022Loss−$112.0M▼ 11.2%—$0

FY2021Loss−$100.8M▼ 27.3%—$0

FY2020Loss−$79.2M▼ 81.0%—$0

Net income vs peers (Healthcare)

AKRO vs peers · net income

#CompanyNet IncomeYoYNet MarginRelative

#1

Akero Therapeutics, Inc.YOU

AKRO

−$252.1M-66.1%—

Loss

Johnson & Johnson

$26.80B+90.6%28.5%

Eli Lilly and Company

$20.64B+94.9%31.7%

UnitedHealth Group Incorporated

$12.06B-16.3%2.7%

$4.23B-1.2%6.9%

Healthcare · Sorted by Net Income · FMP /income-statementFull Net Income Rankings →

About Net Income & Methodology

Akero Therapeutics, Inc. (AKRO) reported net income of −$252.1M for FY2024 (fiscal year ending 2024-12-31), down 66.1% year-over-year. The net profit margin was — — meaning the company kept $— of every dollar of revenue as profit.

Akero Therapeutics, Inc. has not yet achieved annual profitability based on available data (8 fiscal years). The company has reported net losses across all available periods.

Akero Therapeutics, Inc.'s net profit margin was — for FY2024, based on the latest annual results.

Investors sometimes search for "Akero Therapeutics, Inc. net worth" — the company's market capitalization is a separate figure from AKRO net income. Data sourced from FMP /income-statement · US GAAP · USD.

Figures tie to SEC 10-K/10-Q and FMP /income-statement where noted.

Revenue Financial statements Earnings Forecast Price history Market cap Free cash flow

Frequently asked questions

AKRO net income · 4 questions

Akero Therapeutics, Inc. is not currently profitable on an annual basis. The company reported a net loss of $252.1M for FY2024.

is AKRO profitabledoes AKRO make a profitAKRO profitabilityAKRO profitable company

▸ Source: FMP /income-statement · GAAP · Akero Therapeutics, Inc. · Akero Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026